Gagnon Securities LLC Buys 51,494 Shares of Pacira BioSciences, Inc. $PCRX

Gagnon Securities LLC increased its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 11.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 501,211 shares of the company’s stock after purchasing an additional 51,494 shares during the period. Pacira BioSciences accounts for 2.6% of Gagnon Securities LLC’s holdings, making the stock its 14th biggest holding. Gagnon Securities LLC’s holdings in Pacira BioSciences were worth $12,971,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of PCRX. Hantz Financial Services Inc. lifted its position in Pacira BioSciences by 175.4% during the third quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company’s stock valued at $29,000 after acquiring an additional 721 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in shares of Pacira BioSciences by 5,900.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,500 shares of the company’s stock valued at $39,000 after purchasing an additional 1,475 shares during the period. Eurizon Capital SGR S.p.A. purchased a new position in shares of Pacira BioSciences in the fourth quarter worth about $51,000. Global Retirement Partners LLC grew its stake in shares of Pacira BioSciences by 479.4% in the 4th quarter. Global Retirement Partners LLC now owns 2,028 shares of the company’s stock valued at $52,000 after buying an additional 1,678 shares during the period. Finally, Strs Ohio purchased a new stake in shares of Pacira BioSciences in the 1st quarter valued at approximately $75,000. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PCRX. Barclays dropped their price objective on shares of Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating for the company in a report on Thursday, March 26th. Wall Street Zen cut shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Weiss Ratings upgraded shares of Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, May 20th. Needham & Company LLC upped their target price on shares of Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a report on Friday, May 1st. Finally, Royal Bank Of Canada upped their target price on shares of Pacira BioSciences from $22.00 to $24.00 and gave the company a “sector perform” rating in a report on Friday, May 1st. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $29.40.

Insiders Place Their Bets

In other Pacira BioSciences news, SVP Lauren Riker sold 6,115 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $23.50, for a total transaction of $143,702.50. Following the sale, the senior vice president directly owned 62,284 shares of the company’s stock, valued at $1,463,674. This trade represents a 8.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jonathan Slonin sold 3,261 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total transaction of $74,416.02. Following the sale, the insider directly owned 223,640 shares in the company, valued at $5,103,464.80. This represents a 1.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 34,376 shares of company stock valued at $846,312 in the last ninety days. Insiders own 6.40% of the company’s stock.

Pacira BioSciences Stock Down 1.6%

PCRX stock opened at $22.99 on Friday. The company has a fifty day moving average price of $23.58 and a 200 day moving average price of $23.27. Pacira BioSciences, Inc. has a 12 month low of $18.80 and a 12 month high of $27.64. The company has a market cap of $904.66 million, a price-to-earnings ratio of 191.60 and a beta of 0.29. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.73 and a quick ratio of 3.35.

Pacira BioSciences (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, April 30th. The company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Pacira BioSciences had a net margin of 0.70% and a return on equity of 10.24%. The business had revenue of $177.38 million during the quarter, compared to analyst estimates of $171.80 million. During the same period in the previous year, the company posted $0.65 earnings per share. Pacira BioSciences’s revenue was up 5.0% on a year-over-year basis. Sell-side analysts expect that Pacira BioSciences, Inc. will post 1.91 earnings per share for the current year.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.